Kohlberg Kravis Roberts & Co. L.P. Coherus Bio Sciences, Inc. Transaction History
Kohlberg Kravis Roberts & Co. L.P.
- $1.79 Billion
- Q3 2024
A detailed history of Kohlberg Kravis Roberts & Co. L.P. transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Kohlberg Kravis Roberts & Co. L.P. holds 3,036,076 shares of CHRS stock, worth $4.52 Million. This represents 0.18% of its overall portfolio holdings.
Number of Shares
3,036,076
Previous 3,036,076
-0.0%
Holding current value
$4.52 Million
Previous $5.25 Million
39.89%
% of portfolio
0.18%
Previous 0.3%
Shares
2 transactions
Others Institutions Holding CHRS
# of Institutions
135Shares Held
77.9MCall Options Held
40.7KPut Options Held
50.1K-
Black Rock Inc. New York, NY11.8MShares$17.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.3MShares$16.9 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY10.4MShares$15.5 Million0.3% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.86MShares$4.26 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.57MShares$3.82 Million0.0% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $116M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...